Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02970019 · ClinicalTrials.gov registry record · Phase 1
Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 5
- Study locations
NCT02970019: Completed Phase 1 study of Parkinson Disease, sponsored by Sun Pharma Advanced Research Company Limited.
NCT02970019 is a Phase 1 study of Parkinson Disease that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 60 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02970019, a Phase 1 study of Parkinson Disease, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
Conditions Studied
Interventions
- DRUG Placebo
- DRUG K0706
Study Locations (5)
California
- SPARC Site 03 - Long Beach
- SPARC Site 05 - Panorama City
Florida
- SPARC Site 01 - DeLand
- SPARC Site 02 - Orlando
North Carolina
- SPARC Site 04 - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-03-30 |
| Est. Completion | 2019-05-28 |
| Phase | Phase 1 |
What the finished NCT02970019 record still lists
NCT02970019 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02970019 lists 5 locations in 3 states (California, Florida, North Carolina).
Frequently Asked Questions
What is clinical trial NCT02970019 about?
NCT02970019 is a clinical study titled "Safety and Tolerability Study of K0706 in Subjects With Parkinson's Disease". This is a safety, tolerability and pharmacokinetic study in subjects with Parkinson's disease
What is the current status of trial NCT02970019?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-03-30. Estimated completion is 2019-05-28.
What conditions does trial NCT02970019 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT02970019?
The interventions under investigation include: Placebo (DRUG), K0706 (DRUG).
Who is sponsoring clinical trial NCT02970019?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02970019 being conducted?
This trial has 5 study locations across California, Florida, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02970019's enrollment target sits among peer trials
60 125th of 297 higher than 154 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
RECRUITING · Phase 1
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- NCT02114450 · 60 participants · NA
Human-Machine System for the H2 Lower Limb Exoskeleton
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI